HC Wainwright Reaffirms “Buy” Rating for KALA BIO (NASDAQ:KALA)

HC Wainwright reaffirmed their buy rating on shares of KALA BIO (NASDAQ:KALA) in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

Separately, Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of KALA BIO in a report on Monday, August 19th.

KALA BIO Trading Down 0.9 %

Shares of NASDAQ KALA traded down $0.06 during mid-day trading on Friday, reaching $6.70. The company had a trading volume of 9,950 shares, compared to its average volume of 83,803. The stock has a market cap of $30.89 million, a price-to-earnings ratio of -0.54 and a beta of -2.13. KALA BIO has a 52 week low of $4.21 and a 52 week high of $10.97. The business’s 50-day moving average is $6.02 and its 200-day moving average is $6.29. The company has a current ratio of 2.15, a quick ratio of 3.07 and a debt-to-equity ratio of 3.18.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. Equities analysts expect that KALA BIO will post -11.76 earnings per share for the current year.

Hedge Funds Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP bought a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th largest position. SR One Capital Management LP owned 15.76% of KALA BIO as of its most recent filing with the Securities and Exchange Commission (SEC). 24.61% of the stock is currently owned by institutional investors.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.